During the study simply no RCTs comparing therapeutic approaches in MIS-C have been published directly, so suggestions were produced from clinical practice and non-randomized comparative cohort research [25C28]
During the study simply no RCTs comparing therapeutic approaches in MIS-C have been published directly, so suggestions were produced from clinical practice and non-randomized comparative cohort research [25C28]. of respondents; remdesivir and monoclonal antibodies had been recommended by 48.6% and 27.1% of respondents, respectively. For MIS-C, steroids had been recommended…